The primary analysis of the CHANCE trial had found that combined treatment of clopidogrel and aspirin decreases 90-day risk of stroke without increasing haemorrhage in comparison with aspirin alone. A further analysis found that the early benefit of clopidogrel-aspirin treatment in reducing the risk of subsequent stroke persisted for the duration of 1-year of follow-up.